Gračner Tomaž
Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia.
Department of Ophthalmology, University Clinical Centre Maribor, 2000 Maribor, Slovenia.
J Clin Med. 2021 Sep 19;10(18):4249. doi: 10.3390/jcm10184249.
To evaluate whether short-term use of topical steroid therapy affected the efficacy of selective laser trabeculoplasty (SLT) for primary open-glaucoma (POAG).
25 eyes of 25 patients, who used a drop of dexamethasone 0.1% 4 times a day for 7 days as post-laser therapy, formed the Steroid SLT group and 24 eyes of 24 patients, where no topical steroids or nonsteroidal anti-inflammatory agents as post-laser therapy were used, formed the No-steroid SLT group. Success was defined as an intraocular pressure (IOP) lowering exceeding 20% of pretreatment IOP.
The mean follow-up time was 21.24 months for the Steroid SLT group and 20.25 months for the No-steroid SLT group ( = 0.990). No significant difference was found between the two groups for mean pretreatment IOP (22.20 mmHg vs. 22.33 mmHg), and for mean IOP reductions during whole follow-up period. At all follow-up visits, the mean IOP reductions were smaller in the Steroid SLT group than in the No-steroid SLT group. At all follow-up visits, the mean percent IOP reduction was smaller in the Steroid SLT group than in the No-steroid SLT group, and such a difference was significant at 12 months (25.4% vs. 29.6%, = 0.047) and 24 months (25.3% vs. 29.7%, = 0.024). According to the Kaplan-Meier survival analysis, the 24-month success rate was 84% in the Steroid SLT group and 79.2% in the No-steroid SLT group, with no differences between the groups ( = 0.675).
Short-term use of topical steroid therapy had no impact on the efficacy of SLT for POAG.
评估短期局部使用类固醇疗法是否会影响选择性激光小梁成形术(SLT)治疗原发性开角型青光眼(POAG)的疗效。
25例患者的25只眼在激光治疗后每天使用4次0.1%地塞米松滴眼液,共7天,组成类固醇SLT组;24例患者的24只眼在激光治疗后未使用局部类固醇或非甾体抗炎药,组成无类固醇SLT组。成功定义为眼压(IOP)降低超过治疗前眼压的20%。
类固醇SLT组的平均随访时间为21.24个月,无类固醇SLT组为20.25个月(P = 0.990)。两组治疗前平均眼压(22.20 mmHg对22.33 mmHg)以及整个随访期间平均眼压降低幅度均无显著差异。在所有随访中,类固醇SLT组的平均眼压降低幅度均小于无类固醇SLT组。在所有随访中,类固醇SLT组的平均眼压降低百分比均小于无类固醇SLT组,且在12个月时(25.4%对29.6%,P = 0.047)和24个月时(25.3%对29.7%,P = 0.024)差异显著。根据Kaplan-Meier生存分析,类固醇SLT组的24个月成功率为84%,无类固醇SLT组为79.2%,两组之间无差异(P = 0.675)。
短期局部使用类固醇疗法对SLT治疗POAG的疗效无影响。